Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Characterization of Neurodevelopmental Abnormalities in iPSC-Derived Striatal Cultures from Patients with Huntington's Disease.

Mathkar PP, Suresh D, Dunn J, Tom CM, Mattis VB.

J Huntingtons Dis. 2019;8(3):257-269. doi: 10.3233/JHD-180333.

PMID:
31381521
2.

Huntington's Disease Patient-Derived Astrocytes Display Electrophysiological Impairments and Reduced Neuronal Support.

Garcia VJ, Rushton DJ, Tom CM, Allen ND, Kemp PJ, Svendsen CN, Mattis VB.

Front Neurosci. 2019 Jun 28;13:669. doi: 10.3389/fnins.2019.00669. eCollection 2019.

3.

Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites.

Kedaigle AJ, Fraenkel E, Atwal RS, Wu M, Gusella JF, MacDonald ME, Kaye JA, Finkbeiner S, Mattis VB, Tom CM, Svendsen C, King AR, Chen Y, Stocksdale JT, Lim RG, Casale M, Wang PH, Thompson LM, Akimov SS, Ratovitski T, Arbez N, Ross CA.

Hum Mol Genet. 2019 Feb 15. pii: ddy430. doi: 10.1093/hmg/ddy430. [Epub ahead of print]

PMID:
30768179
4.

Human Huntington's Disease iPSC-Derived Cortical Neurons Display Altered Transcriptomics, Morphology, and Maturation.

Mehta SR, Tom CM, Wang Y, Bresee C, Rushton D, Mathkar PP, Tang J, Mattis VB.

Cell Rep. 2018 Oct 23;25(4):1081-1096.e6. doi: 10.1016/j.celrep.2018.09.076.

5.

Cellular Models: HD Patient-Derived Pluripotent Stem Cells.

Geater C, Hernandez S, Thompson L, Mattis VB.

Methods Mol Biol. 2018;1780:41-73. doi: 10.1007/978-1-4939-7825-0_4. Review.

PMID:
29856014
6.

Inducible Expression of GDNF in Transplanted iPSC-Derived Neural Progenitor Cells.

Akhtar AA, Gowing G, Kobritz N, Savinoff SE, Garcia L, Saxon D, Cho N, Kim G, Tom CM, Park H, Lawless G, Shelley BC, Mattis VB, Breunig JJ, Svendsen CN.

Stem Cell Reports. 2018 Jun 5;10(6):1696-1704. doi: 10.1016/j.stemcr.2018.03.024. Epub 2018 Apr 26.

7.

Huntington modeling improves with age.

Mattis VB, Svendsen CN.

Nat Neurosci. 2018 Mar;21(3):301-303. doi: 10.1038/s41593-018-0086-4. No abstract available.

PMID:
29476127
8.

Optimization of trans-Splicing for Huntington's Disease RNA Therapy.

Rindt H, Tom CM, Lorson CL, Mattis VB.

Front Neurosci. 2017 Oct 10;11:544. doi: 10.3389/fnins.2017.00544. eCollection 2017.

9.

Survival of iPSC-derived grafts within the striatum of immunodeficient mice: Importance of developmental stage of both transplant and host recipient.

Tom CM, Younesi S, Meer E, Bresee C, Godoy M, Mattis VB.

Exp Neurol. 2017 Nov;297:118-128. doi: 10.1016/j.expneurol.2017.07.018. Epub 2017 Jul 29.

PMID:
28760579
10.

Modeling Huntington׳s disease with patient-derived neurons.

Mattis VB, Svendsen CN.

Brain Res. 2017 Feb 1;1656:76-87. doi: 10.1016/j.brainres.2015.10.001. Epub 2015 Oct 13. Review.

PMID:
26459990
11.

In Vivo Tracking of Human Neural Progenitor Cells in the Rat Brain Using Magnetic Resonance Imaging Is Not Enhanced by Ferritin Expression.

Bernau K, Lewis CM, Petelinsek AM, Reagan MS, Niles DJ, Mattis VB, Meyerand ME, Suzuki M, Svendsen CN.

Cell Transplant. 2016;25(3):575-92. doi: 10.3727/096368915X688614. Epub 2015 Jul 8.

12.

HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.

Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, Svendsen CN.

Hum Mol Genet. 2015 Jun 1;24(11):3257-71. doi: 10.1093/hmg/ddv080. Epub 2015 Mar 3.

13.

Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.

Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, Waldvogel H, Greiner E, Osmand A, Elzein K, Xiao J, Dijkstra S, de Pril R, Vinters HV, Faull R, Signer E, Kwak S, Marugan JJ, Botas J, Fischer DF, Svendsen CN, Munoz-Sanjuan I, Yang XW.

Sci Transl Med. 2014 Dec 24;6(268):268ra178. doi: 10.1126/scitranslmed.3010523.

PMID:
25540325
14.

Neonatal immune-tolerance in mice does not prevent xenograft rejection.

Mattis VB, Wakeman DR, Tom C, Dodiya HB, Yeung SY, Tran AH, Bernau K, Ornelas L, Sahabian A, Reidling J, Sareen D, Thompson LM, Kordower JH, Svendsen CN.

Exp Neurol. 2014 Apr;254:90-8. doi: 10.1016/j.expneurol.2014.01.007. Epub 2014 Jan 16.

15.

Stimulation of GABA-induced Ca2+ influx enhances maturation of human induced pluripotent stem cell-derived neurons.

Rushton DJ, Mattis VB, Svendsen CN, Allen ND, Kemp PJ.

PLoS One. 2013 Nov 22;8(11):e81031. doi: 10.1371/journal.pone.0081031. eCollection 2013.

16.

EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs.

Ebert AD, Shelley BC, Hurley AM, Onorati M, Castiglioni V, Patitucci TN, Svendsen SP, Mattis VB, McGivern JV, Schwab AJ, Sareen D, Kim HW, Cattaneo E, Svendsen CN.

Stem Cell Res. 2013 May;10(3):417-427. doi: 10.1016/j.scr.2013.01.009. Epub 2013 Feb 4.

17.

Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy.

Mattis VB, Tom Chang CW, Lorson CL.

Neurosci Lett. 2012 Sep 6;525(1):72-5. doi: 10.1016/j.neulet.2012.07.024. Epub 2012 Jul 20.

18.

Induced pluripotent stem cells: a new revolution for clinical neurology?

Mattis VB, Svendsen CN.

Lancet Neurol. 2011 Apr;10(4):383-94. doi: 10.1016/S1474-4422(11)70022-9. Review.

PMID:
21435601
19.

Therapeutics that directly increase SMN expression to treat spinal muscular atrophy.

Shababi M, Mattis VB, Lorson CL.

Drug News Perspect. 2010 Oct;23(8):475-82. doi: 10.1358/dnp.2010.23.8.1507295. Review.

PMID:
21031163
20.

Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA.

Mattis VB, Fosso MY, Chang CW, Lorson CL.

BMC Neurosci. 2009 Nov 30;10:142. doi: 10.1186/1471-2202-10-142.

21.

Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model.

Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL.

Hum Mol Genet. 2009 Oct 15;18(20):3906-13. doi: 10.1093/hmg/ddp333. Epub 2009 Jul 21.

22.

Induced pluripotent stem cells from a spinal muscular atrophy patient.

Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN.

Nature. 2009 Jan 15;457(7227):277-80. doi: 10.1038/nature07677. Epub 2008 Dec 21.

23.

Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Rose FF Jr, Mattis VB, Rindt H, Lorson CL.

Hum Mol Genet. 2009 Mar 15;18(6):997-1005. doi: 10.1093/hmg/ddn426. Epub 2008 Dec 12.

24.

Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.

Mattis VB, Butchbach ME, Lorson CL.

J Neurosci Methods. 2008 Oct 30;175(1):36-43. doi: 10.1016/j.jneumeth.2008.07.024. Epub 2008 Aug 15.

25.

A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein.

Mattis VB, Bowerman M, Kothary R, Lorson CL.

Neurosci Lett. 2008 Sep 5;442(1):54-8. doi: 10.1016/j.neulet.2008.06.059. Epub 2008 Jun 26.

26.

Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts.

Mattis VB, Rai R, Wang J, Chang CW, Coady T, Lorson CL.

Hum Genet. 2006 Nov;120(4):589-601. Epub 2006 Sep 2.

PMID:
16951947

Supplemental Content

Loading ...
Support Center